Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antibiotic Use
10%
Antigen-specific
10%
Atypical Hemolytic Uremic Syndrome (aHUS)
10%
Au Nanoparticles (AuNPs)
60%
Bacteriophage
10%
Causative Agents
10%
Classical Complement Pathway
10%
Diarrhea
10%
Disease Model
10%
E. Coli Pathotypes
10%
Effective Interventions
10%
Enteric Pathogens
10%
Enteroaggregative E. Coli
10%
Enterohemorrhagic Escherichia Coli Infection
10%
Enteropathogenic E. Coli
10%
Escc
50%
Escherichia Coli
10%
Escherichia Coli O157:H7
100%
Feces
10%
Global Public Health Problem
10%
Gold Nanoparticles
100%
Gold Nanoparticles(AuNPs)
10%
Hemorrhagic Colitis
10%
Human Infection
10%
Human Intestinal Epithelial Cells
10%
Human Pathogens
10%
Human Use
10%
IgG Titer
20%
Immunogenic Antigen
10%
Immunogenicity
20%
Intervention Control
10%
Intestinal Colonization
10%
Nanoparticle Platform
10%
Nanoparticle Synthesis
20%
Nanoparticle Vaccine
100%
Nanoparticles
10%
Nanovaccine
20%
Natural Properties
10%
Outer Membrane
10%
Outer Membrane Protein
10%
Public Health Interventions
10%
Public Health Safety
10%
Recurrent Outbreaks
10%
Safety Control Measures
10%
Secretory Immunoglobulin A (SIgA)
10%
Serum IgA
10%
Serum IgG
10%
Stable Formulation
10%
Subcutaneous Immunization
10%
Subunit Vaccine
10%
Titer
10%
Type 3 Secretion System (T3SS)
10%
Vaccine Development
10%
Immunology and Microbiology
Antigen
50%
Antigen Specificity
10%
Bactericidal Activity
10%
Bacteriophage
10%
Classical Complement Pathway
10%
Colitis
10%
Enteroaggregative Escherichia Coli
10%
Enterohemorrhagic Escherichia Coli
100%
Enteropathogenic Escherichia Coli
10%
Escherichia coli
20%
Escherichia Coli O157:H7
100%
Feces
10%
Human Pathogen
10%
Immunogenicity
20%
Infection
20%
Infectious Agent
10%
Infectious Disease
20%
Outer Membrane
20%
Secretory Immunoglobulin
10%
Subunit Vaccine
10%
Titer
30%
Type Three Secretion System
10%